Inamed Breast Implant Panel Nod Helps Boost Stock 31% In March
This article was originally published in The Gray Sheet
Inamed stock enjoyed a 31% price jump in March to 49-1/2 as a favorable recommendation by an FDA panel reassured investors that the McGhan division's saline breast implants would remain on the market.
You may also be interested in...
Bausch & Lomb's unsolicited offer for cosmetic contact lens manufacturer Wesley Jessen VisionCare will have to take into account a $20 mil. one-time charge the latter will face if it walks away from a previously announced definitive merger agreement with Ocular Sciences.
Inamed's McGhan Medical unit should eliminate non-significant risks from its risk characterization of saline breast implants as a condition for FDA approval, the agency's General and Plastic Surgery Devices advisory panel concluded March 2 in Gaithersburg, Maryland.
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.